KEYNOTE-859 (MK3475-859)

Name No. For Patients with Purpose
KEYNOTE-859 (MK3475-859) 18-30

Previously untreated HER2 negative advanced cancer of the stomach or the junction between the stomach and the oesophagus (gastrooesophageal junction).

This trial will compare the effectiveness of a drug called Pembrolizumab used in combination with chemotherapy, to a placebo used in combination with chemotherapy.

Patients will be randomly assigned (randomised) between either Pembrolizumab and chemotherapy, or placebo and chemotherapy.


MK3475-811 (KEYNOTE 811)

Name No. For Patients with Purpose
MK3475-811 (KEYNOTE 811) 18-12

Cancer of the oesophagus or gastro-oesophageal junction which has spread (metastasised).

To compare survival between the two groups – those treated with Trastuzumab, chemotherapy and Pembrolizumab and those treated with Trastuzumab, chemotherapy and placebo.


COLOSSUS

Name No. For Patients with Purpose
COLOSSUS 17-26

Patients with cancer of the colon which has spread (metastasised).

The aim of the study is to identify and confirm one or more biomarkers (a biological substance) in blood and/or tissue, which will help us to identify the patients, who are going to respond to their treatment.